Biomarkers, Proteoforms, and Mass Spectrometry-Based Assays for Diabetes Clinical Research

Area of Science:

• Endocrinology
• Biomarker Discovery
• Analytical Chemistry

Background:

• Diabetes mellitus, especially type 2 and type 1 diabetes (T1D), is a growing global health concern.
• Current diabetes research faces challenges due to a lack of reliable circulating pancreatic biomarkers and clinical-grade assays.
• This limits the accurate assessment of disease progression and treatment efficacy.

Purpose of the Study:

• To review emerging pancreatic biomarkers for diabetes, with a focus on T1D.
• To discuss the limitations of existing immunoassays for diabetes biomarker detection.
• To highlight the increasing utility of mass spectrometry-based assays in diabetes research.

Main Methods:

• Literature review of emerging pancreatic biomarkers and assay technologies.
• Discussion of limitations in current immunoassay techniques.
• Emphasis on mass spectrometry-based assays, including proteoform-specific approaches.
• Highlighting the NIDDK-funded TaMADOR consortium's work.

Main Results:

• Emerging pancreatic biomarkers show promise for T1D research.
• Mass spectrometry offers a more robust and quantitative approach compared to traditional immunoassays.
• The TaMADOR consortium is developing transferable assays for translational research.
• Proteoform-specific assays are crucial for monitoring pancreatic prohormone processing.

Conclusions:

• Advancements in biomarker discovery and assay technology, particularly mass spectrometry, are crucial for overcoming current limitations in diabetes research.
• Developing robust, quantitative, and proteoform-specific assays will enhance the monitoring of pancreatic function and therapeutic responses in T1D and other forms of diabetes.